The first application of Ga-68 and Lu-177 theranostics in the Philippines: A rare case of mediastinal small cell neuroendocrine carcinoma
- Author:
Emily Mia C. Acayan
1
;
Patricia A. Bautista
1
;
Miguel Antonio C. Catangui
1
;
Raquel Marie R. Cabatu-Key
1
Author Information
1. Department of Nuclear Medicine and PET Center, St. Lukes Medical Center, Quezon City. Philippines
- Publication Type:Case Reports
- Keywords:
68Ga-DOTATATE;
177Lu-DOTATATE
- MeSH:
Precision Medicine;
Philippines;
Carcinoma, Neuroendocrine
- From:
The Philippine Journal of Nuclear Medicine
2019;14(1):5-8
- CountryPhilippines
- Language:English
-
Abstract:
A 43-year-old female with a surgically unresectable and non-secretory mediastinal small cell neuroendocrine carcinoma waws previously given the protein kinase inhibitor Everolimus with intolerable nausea and fatigue. High somatostatin receptor expression of the known tumor was seen on 68Ga-DOTATATE PET/CT scan. She was then given 6.4 GBq of 177 Lu-DOTATATE with no adverse events. A follow-up 68Ga-DOTATATE PET/CT scan three months post-treatment showerd stable DOTATATE affinity with no evidence of metastasis. this case presents an overview of peptide receptor radionuclide therapy (PRRT), especially for multidisciplinary teams in the Philippines, as 68Ga and 177 Lu theranostics is introduced in the country.
- Full text:The First Application.pdf
